Navigation Links
New PCR Primers for Human Diseases

Screen samples for disease states or pathogens

Gabriela M. Tobal
Stratagene Cloning Systems, Inc.

W. S. Nichols

Stratagene is introducing PCR primer sets for detecting 13 human diseases. The sequences of these primers have been published previously and are well characterized. With these tested primer sets, medical researchers can use PCR technology to identify the presence of many human diseases.

Molecular detection and genetic characterization of human disease are key components of current research in medicine. In order to detect the presence of genetic mutation and infectious agents, PCR is used routinely in research laboratories. The speed and sensitivity of PCR-based assays allow shorter detection times for bacterial and viral pathogens whose detection would otherwise require culturing and staining of samples, detecting metabolic products and performing serologic tests.

To aid in the diagnosis of specific diseases in biological materials, Stratagene is introducing a series of PCR primers that are derived from sequences published in GenBank. These human disease primers amplify genes from samples infected with the following organisms: Human immunodeficiency virus, type 1 (HIV-1),1,2 hepatitis B (HBV),3 hepatitis C (HCV) (RT-PCR primers*, use cDNA as template),4,5 herpes simplex virus, types 1 and 2 (HSV-1, HSV-2),6-8 human herpesvirus 6 (HHV-6),9,10 parvovirus B19,11 genital human papillomavirus (HPV),12-14 cytomegalovirus (CMV),15,16 Toxoplasma gondii,17 varicella-zoster virus (VZV),18 Epstein-Barr virus (EBV)19 and adenovirus.20 Primers to detect the human coagulation factor V (Leiden) mutation21 are also available.

PCR Assays of Primer Sets

Figure 1

Figure 2

Each primer set was used in PCR amplifications of DNA templates from infected serum samples, with genomic DNA from infected cells or with cDNA made from RNA isolated from infected cells. The control reactions were performed with DNA from both uninfected sera and human cells. The specificity of each primer set is shown in figure 1. Each amplification yielded a single product of the appropriate size in reactions with DNA from infected serum samples (figure 1 and figure 2), whereas amplification products were not detected in any of the negative controls, uninfected serum samples (figure 1).

Assay for the Factor V Mutation

The factor V (Leiden) mutation is associated with thrombophilia. In order to test for a point mutation of G1691A, the gene coding for human coagulation factor V, the factor V (Leiden) mutation assay is used. This assay requires an initial PCR amplification with subsequent digestion with the Mnl I restriction enzyme that yields a restriction fragment length polymorphism for the wild-type, heterozygous and homozygous genotypes (figure 2). Stratagenes primer set for performing the factor V mutation assay includes the Mnl I enzyme and the corresponding restriction enzyme buffer.

Conclusions

PCR technology is a powerful method for amplifying specific regions of DNA and can be used for detecting pathogens or mutations in DNA samples. Because PCR is capable of amplifying extremely small amounts of bacterial or viral DNA, it can be used for early detection of disease. Medical researchers can use Stratagenes Primer Sets for Human Diseases to screen DNA samples for the specified pathogens or mutations. Stratagene has packaged groups of primer sets, available at reduced rates.

REFERENCES

  1. Kwok, S., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 309-315. American Society for Microbiology, Washington, D.C.

  2. Kwok, S., et al. (1990) Nucleic Acids Res. 18: 999-1005.

  3. Yokosuka, O., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 322-326. American Society for Microbiology, Washington, D.C.

  4. Cha, T., et al. (1991) J. Clin. Microbiol. 29: 2528-2534.

  5. Wilbur, J.C., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 327-331. American Society for Microbiology, Washington, D.C.

  6. Cone, R.W., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 337-343. American Society for Microbiology, Washington, D.C.

  7. Cone, R.W., et al. (1991) J. Infect. Dis. 164: 757-760.

  8. Stuve, L.L., et al. (1987) J. Virol. 61: 326-335.

  9. Klotman, M.E., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 501-510. American Society for Microbiology, Washington, D.C.

  10. Buchbinder, A., et al. (1988) J. Virol. Methods 21: 191-197.

  11. Clewley, J.P. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 367-373. American Society for Microbiology, Washington, D.C.

  12. Bauer, H.M., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 407-413. American Society for Microbiology, Washington, D.C.

  13. Bauer, H. M., et al. (1991) JAMA. 265: 472-477.

  14. Manos, M.M., et al. (1989) Cancer Cells 7: 209-214.

  15. Espy, M.J., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 350-355. American Society for Microbiology, Washington, D.C.

  16. Shibata, D.W., and Martin, J. (1988) J. Infect. Dis. 158: 1185-1192.

  17. Burg, L.J., et al. (1989) J. Clin. Microbiol. 27: 1787-1792.

  18. Puchhammer-Stockl, E. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 356-360. American Society for Microbiology, Washington, D.C.

  19. Telenti, A. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 344-349. American Society for Microbiology, Washington, D.C.

  20. Kew, O., et al. (1993) In Diagnostic Molecular Microbiology: Principles and Applications, pp. 389-393. American Society for Microbiology, Washington, D.C.

  21. Ridker, P.M., et al. (1995) N. Engl. J. Med. 332: 912-917.


'"/>

Source:


Page: All 1 2 3 4

Related biology technology :

1. Control RT-PCR Primers for Human Gene Transcripts with Varying Abundance
2. Gene-Specific Primers for NMDA Receptor Subunits
3. RT-PCR Primers for the Study of Apoptosis
4. Amplification of Epstein-Barr Virus Exon C with Difficult Primers Using Eppendorf Mastercycler gradient
5. Human Primary Preadipocytes and Differentiated Adipocytes
6. Low Abundance cDNA Cloned Using Stratagenes Human Universal cDNA Library
7. New Mammalian Expression Vectors Employ Stable, High-Level Fluorescence Humanized Renilla GFP Reporter
8. Human Universal cDNA Library Array I
9. Map and Link Human Genetic Disorders with SSLP Analysis
10. RT-PCR Primer Sets for Human and Mouse Mismatch Repair Genes
11. Transfection of Green Fluorescent Protein into Human Adrenalcarcinoma Cells
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/24/2017)... , March 24, 2017 Agenus Inc. (NASDAQ: ... checkpoint antibodies and cancer vaccines, today announced participation at ... th  Annual William Blair and Maidstone Life Sciences conference ... Center in New York, NY . ... March 29 at 9:40 am: Robert B. Stein ...
(Date:3/23/2017)... ... 23, 2017 , ... Lajollacooks4u is proud to announce it has become the premiere team-building cooking ... for companies around the world, such as Illumina, HP and Qualcomm, and is ranked #1 ... increasing popularity is due to its new team building format, a way for teams to ...
(Date:3/23/2017)...  Northwest Biotherapeutics (OTCQB: NWBO) (NW Bio), a ... solid tumor cancers, today announced that yesterday it ... last Friday, March 17, 2017. ... totaling 28,843,692 shares, comprised of 18,843,692 common shares ... Class C Warrants pre-funded at the closing at ...
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
Breaking Biology Technology:
(Date:3/2/2017)... Summary This report provides all ... and its partnering interests and activities since 2010. ... The Partnering Deals and Alliance since 2010 report provides ... of the world,s leading life sciences companies. ... ensure inclusion of the most up to date deal ...
(Date:2/28/2017)... , February 28, 2017 News solutions ... ... Amsterdam from 14 to 16 March, Materna will ... and show how seamless travel is a real benefit for passengers. ... added biometrics to their passenger touch point solutions to take passengers ...
(Date:2/22/2017)... 22, 2017 With the biometrics market ... identifies four technologies that innovative and agile startups ... share in the changing competitive landscape: multifactor authentication ...   "Companies can no longer afford ... says Dimitrios Pavlakis , Industry Analyst at ...
Breaking Biology News(10 mins):